However, unlike in other cancers, PD-L1 expression was not predictive of response to pembrolizumab in patients with HCC.11 Further research is therefore needed to discover the biomarkers to aid in patient selection that would in turn improve the value of anti–PD-1 therapy. The gene discussed is CD274; the disease is hepatocellular carcinoma.